| Entry |
|
|---|
| Name |
Sorafenib (USAN/INN)
|
|---|
| Formula |
C21H16ClF3N4O3
|
|---|
| Exact mass |
464.0863
|
|---|
| Mol weight |
464.825
|
|---|
| Structure |
     |
|---|
| Activity |
Antineoplastic;
Anticancer;
Cytostatic, cytostaticum [DS: H00021 H00048]
|
|---|
| Remark |
|
|---|
| Comment |
Raf inhibitor
Indications: Hepatocellular carcinoma, Renal Cell carcinoma
|
|---|
| Target |
BRAF inhibitor [HSA: 673] [KO: K04365]; FLT3 inhibitor [HSA: 2322] [KO: K05092]; PDGFRB tyrosine kinase inhibitor [HSA: 5159] [KO: K05089]; VEGFR2 tyrosine kinase inhibitor [HSA: 3791] [KO: K05098]; VEGFR3 tyrosine kinase inhibitor [HSA: 2324] [KO: K05097]; c-KIT tyrosine kinase inhibitor [HSA: 3815] [KO: K05091] |
|---|
| Pathway |
|
|---|
| Metabolism |
|
|---|
| Interaction |
|
|---|
| Structure map |
| Antineoplastics - protein kinases inhibitors |
|
|---|
| Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XE Protein kinase inhibitors
L01XE05 Sorafenib
D08524 Sorafenib (USAN/INN)
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Multitargeted Kinase Inhibitors, Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors
Sorafenib
D08524 Sorafenib (USAN/INN)
Target-based classification of drugs [BR:br08310]
Cytokine receptors
Receptor tyrosine kinase
RTK class III (PDGF receptor family)
PDGFRB tyrosine kinase [HSA:5159] [KO:K05089]
Sorafenib [ATC:L01XE05]
D08524 Sorafenib (USAN/INN)
c-KIT tyrosine kinase [HSA:3815] [KO:K05091]
Sorafenib [ATC:L01XE05]
D08524 Sorafenib (USAN/INN)
Fms-related tyrosine kinase 3 [HSA:2322] [KO:K05092]
Sorafenib [ATC:L01XE05]
D08524 Sorafenib (USAN/INN)
RTK class V (VEGF receptor family)
VEGFR2 tyrosine kinase [HSA:3791] [KO:K05098]
Sorafenib [ATC:L01XE05]
D08524 Sorafenib (USAN/INN)
VEGFR3 tyrosine kinase [HSA:2324] [KO:K05097]
Sorafenib [ATC:L01XE05]
D08524 Sorafenib (USAN/INN)
Protein kinases
Serine/threonine protein kinases: TKL group
RAF family
BRAF [HSA:673] [KO:K04365]
Sorafenib [ATC:L01XE05]
D08524 Sorafenib (USAN/INN)
Antineoplastics [BR:br08308]
Molecularly targeted agents
Receptor tyrosine kinase inhibitors
Sorafenib [ATC:L01XE05]
D08524 Sorafenib (USAN/INN)
 |
|---|
| Other DBs |
CAS: 284461-73-0 PubChem: DrugBank: PDB-CCD: LigandBox: NIKKAJI: |
|---|
| KCF data |
ATOM 32
1 C8x C 30.1700 -18.6200
2 C8y C 30.1700 -20.0200
3 C8x C 31.3600 -20.7200
4 C8x C 32.6200 -20.0200
5 C8y C 32.6200 -18.6200
6 C8y C 31.3600 -17.9200
7 X Cl 33.8100 -17.9200
8 C1d C 31.3600 -16.5200
9 X F 31.3600 -15.1200
10 N1b N 28.9800 -20.7200
11 C5a C 27.7200 -20.0200
12 N1b N 26.5300 -20.7200
13 O5a O 27.7200 -18.6200
14 C8y C 25.3400 -20.0200
15 C8x C 25.3400 -18.6200
16 C8x C 24.1500 -17.9200
17 C8y C 22.9600 -18.6200
18 C8x C 22.9600 -20.0200
19 C8x C 24.1500 -20.7200
20 O2a O 21.7000 -17.9200
21 C8y C 20.5100 -18.6200
22 C8x C 19.3200 -17.9200
23 C8y C 18.1300 -18.6200
24 N5x N 18.1300 -20.0200
25 C8x C 19.3200 -20.7200
26 C8x C 20.5100 -20.0200
27 C5a C 16.8700 -17.9200
28 N1b N 15.6800 -18.6200
29 O5a O 16.8700 -16.5200
30 C1a C 14.4900 -17.9200
31 X F 29.9600 -16.5200
32 X F 32.7600 -16.5200
BOND 34
1 1 2 2
2 2 3 1
3 3 4 2
4 4 5 1
5 5 6 2
6 1 6 1
7 5 7 1
8 6 8 1
9 8 9 1
10 2 10 1
11 10 11 1
12 11 12 1
13 11 13 2
14 12 14 1
15 14 15 2
16 15 16 1
17 16 17 2
18 17 18 1
19 18 19 2
20 14 19 1
21 17 20 1
22 20 21 1
23 21 22 2
24 22 23 1
25 23 24 2
26 24 25 1
27 25 26 2
28 21 26 1
29 23 27 1
30 27 28 1
31 27 29 2
32 28 30 1
33 8 31 1
34 8 32 1
|
|---|
